News

Vegetarians less likely to develop colorectal cancer


 

References

A vegetarian diet reduced the risk of colorectal cancer, according to an analysis of a large, prospective study.

Among 77,659 participants in the Adventist Health Study 2, pescovegetarians (ate fish but not other meats) had the lowest adjusted risk of colorectal cancer, with a hazard ratio of 0.57, compared with nonvegetarians, according to Dr. Michael J. Orlich of Loma Linda (Calif.) University and his associates.

©Ron Chapple Studios/thinkstockphotos.com

For vegans, the hazard ratio was 0.84; for lacto-ovo vegetarians (consumed eggs/dairy), the hazard ratio was 0.82; and for semivegetarians (ate meat less than once a week), the hazard ratio was 0.92. Only the difference between pescovegetarians and nonvegetarians was statistically significant.

The adjusted hazard ratio for all vegetarians was 0.78, a significant difference. There were no significant differences between men or women, or between ethnicities.

Although the increased benefit that pescovegetarians saw likely stems from long chain fatty acid consumption, “analysis may elucidate whether the reduced risk seen in the pescovegetarian group is attributable to fish consumption or to other aspects of the diet,” the investigators said.

Find the full study in JAMA Internal Medicine (doi:10.1001/jamainternmed.2015.59).

Recommended Reading

Infliximab most common cause of drug-induced liver injury
MDedge Family Medicine
Stress independently predicts peptic ulcers
MDedge Family Medicine
Death rates rising for liver cancer, falling for colorectal cancer
MDedge Family Medicine
C. difficile responsible for nearly a half million infections in the United States
MDedge Family Medicine
Emulsifiers alter gut bacteria in mice, set the stage for IBD and metabolic syndrome
MDedge Family Medicine
C. difficile burden in U.S. documented in 2011 estimates of infections, deaths
MDedge Family Medicine
What you must know before you recommend a probiotic
MDedge Family Medicine
Environmental factors could increase U.S. anthrax cases
MDedge Family Medicine
ASCEND trial to test HCV treatment in primary care setting
MDedge Family Medicine
Biologics: Timing of use in IBD still variable
MDedge Family Medicine